Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024. In the quarter to June 2026, revenue grew 466.4%, EPS grew 34.7%, free cash flow grew 9.97% and total debt fell 62.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYMR
Kymera Therapeutics, Inc. (KYMR) Dividend Safety Score
Kymera Therapeutics, Inc.'s Dividend Safety Score for fiscal 2025 cannot be worked out: does not pay a regular dividend.
Dividend Safety Score, annual
Annual newest first
| Period | Dividend Safety Score | Change (points) |
|---|
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Payout of earnings earnings at or below zero | — | — | Fail | 0 |
| Payout of free cash flow free cash flow at or below zero | — | — | Fail | 0 |
| Net debt / EBITDA net cash | — | — | Pass | 20 |
| Years without a dividend cut | 0 | — | Fail | 0 |
| Years of falling or negative earnings over the last 7 fiscal years | 8 | — | Fail | 0 |
| Dividend Safety Score | n/a — does not pay a regular dividend | — | ||
How the stockrow Dividend Safety Score works
Our own composite, out of 100, for the latest fiscal year: up to 25 points for how little of its earnings the dividend takes, 25 for how little of its free cash flow, 20 for net debt against EBITDA, 20 for the years it has paid without a cut and 10 for how steady earnings per share have been over ten years. How we calculate it.
| 80–100 | Well covered |
|---|---|
| 60–79 | Adequately covered |
| 40–59 | Stretched |
| below 40 | Weakly covered |
Not worked out for a company that pays no regular dividend, for banks and REITs, whose payouts and leverage these measures do not describe, or with fewer than five years of earnings.
Dividend Safety Score against peers
| Company | Dividend Safety Score |
|---|---|
| KRYS Krystal Biotech, Inc. compare | — |
| CAI Caris Life Sciences,�Inc. compare | — |
| KYMR Kymera Therapeutics, Inc. | — |
| PTGX Protagonist Therapeutics, Inc. compare | — |
| ABVX Abivax SA Sponsored ADR compare | — |
| CYTK Cytokinetics, Incorporated compare | — |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | — |
| AXSM Axsome Therapeutics, Inc. compare | — |
| TGTX TG Therapeutics, Inc. compare | — |
What Dividend Safety Score is
The stockrow Dividend Safety Score rates how well earnings and free cash flow cover the dividend, with leverage, the dividend’s record and stable earnings.
Up to 25 points for the payout of earnings, 25 for the payout of free cash flow, 20 for net debt ÷ EBITDA, 20 for the years without a dividend cut and 10 for stable earnings